<DOC>
	<DOCNO>NCT01210846</DOCNO>
	<brief_summary>The purpose study obtain QTc data , assess effect tivozanib ECG morphology , determine pharmacokinetic pharmacodynamic ( PK-PD ) relationship observe change cardiac repolarization ( define QTcF duration ) serum concentration tivozanib .</brief_summary>
	<brief_title>A Cardiac Safety Study Tivozanib Evaluate Electrocardiogram Pharmacokinetic-Electrocardiogram Dynamics Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>Tivozanib novel potent pan-vascular endothelial growth factor ( VEGF ) receptor ( VEGFR ) tyrosine kinase inhibitor potent activity 3 VEGFRs ( VEGFR-1 , -2 , -3 ) . In nonclinical model study perform human , tivozanib show strong antiangiogenesis antitumor activity . This study open-label , non-randomized , exploratory single-arm trial evaluate ECG pharmacokinetic ( PK ) -ECG relationship , , tivozanib subject advance solid tumor . The purpose study evaluate ECG interval morphology follow treatment tivozanib subject advance solid tumor determine relationship , , change QTc duration serum concentration tivozanib time subject advance solid tumor .</detailed_description>
	<criteria>Inclusion Criteria Males female , ≥18 year age ; Diagnosis advance solid tumor malignancy histological cytological evidence ; Advanced malignancy , metastatic unresectable , recur progress follow standard therapy fail standard therapy ; standard therapy currently exist ; subject candidate , unwilling undergo standard therapy ; Tumor currently amenable curative surgical intervention ; Recovery effect prior surgery , radiotherapy , systemic antineoplastic therapy ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , life expectancy ≥ 3 month ; Well control thyroid function , opinion Investigator ; Able comprehend willing sign Informed Consent Form ( ICF ) able adhere dose visit schedule . Exclusion Criteria Women breastfeeding , pregnant , intend become pregnant ; Primary central nervous system ( CNS ) malignancies CNS metastasis ; subject previously treat brain metastasis allow brain metastasis stable without steroid treatment least 3 month follow prior treatment ( radiotherapy surgery ) ; Clinically significant cardiac disease ( New York Heart Association class &gt; 2 ) include unstable angina , acute myocardial infarction within 6 month Day 1 , congestive heart failure , arrhythmia require therapy , exception extra systole minor conduction abnormality , per Investigator judgment ; Uncontrolled hypertension : systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 100 mmHg 2 antihypertensive medication , document 2 consecutive measurement take least 24 hour apart ; Baseline ECG , QTcF &gt; 480 m . If screen QTcF &gt; 480 m , may repeat QTcF ≤ 480 m subject enrol ; Any follow hematologic abnormality : • hemoglobin &lt; 9.0 g/dL ; • Absolute neutrophil count &lt; 1500 per mm3 ; platelet count &lt; 100,000 per mm3 ; INR &gt; 1.5 x upper limit normal ( ULN ) ; Any follow serum chemistry urine abnormality : • total bilirubin &gt; 1.5 × ULN ( &gt; 2.5 × ULN subject Gilbert 's syndrome ) ; AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver metastasis ) ; alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN subject liver bone metastasis ) ; creatinine &gt; 2.0 × ULN ; proteinuria &gt; 3+ urinalysis ; Non heal wound , bone fracture , skin ulcer ; Active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , gastrointestinal condition increase risk perforation ; history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 4 week prior administration first dose study drug ; Serious/active infection infection require parenteral antibiotic antifungal therapy ; Inadequate recovery prior surgical procedure major surgical procedure within 4 week prior administration first dose study drug ; Significant thromboembolic vascular disorder surgery within 6 month prior administration first dose study drug , include limited : • deep vein thrombosis ; • pulmonary embolism ; • cerebrovascular accident transient ischemic attack ; • peripheral arterial ischemia &gt; Grade 2 ; • coronary peripheral artery bypass graft ; Significant bleeding disorder within 6 month prior administration first dose study drug , include limited : • hematemesis , hematochezia , melena gastrointestinal bleeding ≥ Grade 2 ; hemoptysis pulmonary bleeding ≥ Grade 2 ; hematuria genitourinary bleed ≥ Grade 2 ; Currently active second primary malignancy , include hematologic malignancy ( leukemia , lymphoma , multiple myeloma , etc ) , non melanoma skin cancer , nonmetastatic prostate cancer , situ cervical cancer ductal lobular carcinoma situ breast . Subjects consider currently active malignancy complete anticancer therapy disease free &gt; 2 year ; History genetic acquire immune suppression disease human immunodeficiency virus ( HIV ) , subject immune suppressive therapy organ transplant ; Lifethreatening illness organ system dysfunction compromise safety evaluation ; Inability swallow pill , malabsorption syndrome gastrointestinal disease severely affect absorption tivozanib , major resection stomach small bowel , gastric bypass procedure ; Psychiatric disorder alter mental status precluding inform consent necessary testing ; History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator ; Use Seville orange grapefruitcontaining food beverage within 72 hour prior Day 1 ; Poor venous access ; Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study ; Sexually active male premenopausal female subject ( partner ) unless agree use adequate contraceptive measure , study 30 day last dose study drug . All fertile male female subject ( partner ) must agree use highly effective method contraception . Highly effective birth control include ( ) IUD plus one barrier method ; ( b ) two barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . Note : Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , consider effective study . Drugs Other Treatments Excluded Prohibited 4 week prior first dose duration study : Chemotherapy , biological therapy ( include cytokine , signal transduction inhibitor , monoclonal antibody ) , immunotherapy , experimental therapy therapy treatment advance solid tumor ; Systemic hormonal therapy , exception : i. hormonal therapy appetite stimulation contraception ; ii . nasal , ophthalmic , inhaled topical steroid preparation ; iii . androgen suppression therapy nonmetastatic prostate carcinoma ; iv . hormone replacement therapy condition adrenal insufficiency , hypothyroidism , etc . ; v. lowdose maintenance steroid therapy ( equivalent prednisone ≤ 10 mg/day ) condition ; Prohibited 3 week prior first dose duration study : Treatment radiotherapy ( limited radiotherapy involve ≤ 25 % bone marrow may allow palliative purpose consultation medical monitor , treatment study drug must stop radiotherapy ) ; Prohibited 2 week prior first dose duration study : Herbal preparations/supplements/topical application ( except daily multivitamin/mineral supplement contain herbal component ) ; Treatment CYP3A4 inducer inhibitor ( see Appendix C examples ) ; Prohibited 1 week prior first dose duration study : Treatment full dose oral anticoagulant warfarin , acenocoumarol , fenprocoumon , similar agent . If previously receive type agent , minimum washout 1 week document PT &lt; 1.5 × ULN require prior start therapy . Full dose anticoagulation low molecular weight heparin unfractionated heparin administer subcutaneously allow . Low dose oral anticoagulation ( eg , 12 mg/day warfarin ) allow provide PT remain &lt; 1.5 × ULN study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>AV-951</keyword>
	<keyword>tivozanib</keyword>
	<keyword>QTc</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>